The drug's regulatory path in both the US and EU has suffered significant setbacks, with no clear path to approval without new financing. Traders should monitor for any capital raise announcements (dilutive offering) and further regulatory updates; the stock is likely to remain under pressure until a credible re-submission plan and funding are secured.
Price Chart
Executive Summary
Nymox Pharmaceutical provided an update on its drug Nymozarfex (TM) for BPH. The initial US submission was not accepted for review, and submissions to Denmark and UK agencies were both refused after full review. The company plans to pursue a US re-submission but stated that updated re-submissions will require additional financing due to current financial limits.
Key Facts
- Initial US submission for Nymozarfex was not accepted to be reviewed.
- Submissions to Denmark and UK agencies were accepted for full review but initially refused.
- UK decision will not be appealed at this time.
- Updated re-submissions will require additional financing due to current financial limits.
- Phase 3 long-term data has a p value of .0003 vs placebo, per the company.
Financial Impact
No specific dollar amounts provided; company explicitly states updated re-submissions require additional financing, indicating a capital need with no disclosed timeline or amount.
Risk Factors
- No timeline or financing plan disclosed for re-submissions.
- Regulatory skepticism around placebo effect and long-term efficacy persists.
- Reliance on a single drug candidate with no approved products or revenue stream.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001640334-26-000983 |
| Document: nymox_ex991.htm | 0001640334-26-000983 |
| Document: 0001640334-26-000983-index-headers.html | 0001640334-26-000983 |
| Document: 0001640334-26-000983-index.html | 0001640334-26-000983 |
| Document: 0001640334-26-000983.txt | 0001640334-26-000983 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 6w ago | 20-F | $0.000200 $0.000200 | · 0.00% | ▼ −0.46% | $0.0600 (−29900.00%) |
Aug 31, 2026 8w ago | 6-K | $0.000200 $0.000200 | · 0.00% | ▲ +0.69% | $0.0600 (+29900.00%) |
Aug 7, 2026 11w ago | 6-K | $0.000200 $0.000200 | · 0.00% | ▲ +0.03% | $0.0600 (+29900.00%) |
Jun 3, 2026 20w ago | 6-K | $0.1269 $0.0646 | ▲ +49.09% | ▲ +49.50% | $0.0600 (+52.72%) |
Mar 27, 2026 30w ago | 6-K | $0.0705 $0.0700 | ▼ −0.71% | ▼ −3.60% | $0.0600 (−14.89%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers